INSMED Inc (INSM)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$582.2M
Cash & Equivalents
$222.7M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$23,062M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
AMIKACIN SULFATE
ARIKAYCE KIT |
APPROVED | Amyotrophic Lateral Sclerosis, Bronchiectasis, Chronic Rhinosinusitis Without Nasal Polyps, Covid19, Cystic Fibrosis, Duchenne Muscular Dystrophy, Growth Hormone Insensitivity Syndrome (GHIS), Healthy Participants, Healthy Volunteer, Healthy Volunteers, Hepatic Impairment, Hidradenitis Suppurativa, Interstitial Lung Disease, Laron Syndrome, Mycobacteria, Atypical, Mycobacterium Infections, Nontuberculous, Myotonic Dystrophy Type 1, Non-Cystic Fibrosis Bronchiectasis, Non-Tuberculous Mycobacterial Pneumonia, Noonan Syndrome, NTM Lung Infection Due to MAC, Osteosarcoma Metastatic, Prostate Cancer, Pseudomonas Aeruginosa Infection, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Renal Impairment |
|
BRENSOCATIB
BRINSUPRI |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.